Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Rating of “Moderate Buy” by Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been given an average recommendation of “Moderate Buy” by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $35.70.

Several research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Royal Bank of Canada upped their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently made changes to their positions in the business. R Squared Ltd acquired a new position in Viridian Therapeutics in the fourth quarter worth about $26,000. Foresite Capital Management VI LLC acquired a new position in shares of Viridian Therapeutics in the 4th quarter worth approximately $38,000. AlphaQuest LLC lifted its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock worth $54,000 after buying an additional 1,519 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Viridian Therapeutics in the 3rd quarter valued at $149,000. Finally, Summit Investment Advisors Inc. grew its position in Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after acquiring an additional 1,516 shares during the period.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $14.16 on Thursday. The firm has a market capitalization of $1.15 billion, a PE ratio of -3.29 and a beta of 1.05. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $16.87 and its 200 day simple moving average is $19.73.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.